secwatch.observer — SEC 8-K summary
======================================

Issuer:     InfuSystem Holdings, Inc (INFU)
CIK:        0001337013
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001628280-24-011061
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InfuSystem reports FY2023 record revenue $125.8M, +14%; EPS $0.04; guides FY2024 high-single-digit growth
--------------------------------------------------------------------------------

- FY2023 net revenue $125.8M (+14% YoY); Patient Services $76.5M (+11%), Device Solutions $49.2M (+20%).
- Q4 net revenue $31.8M (+10%); net income $0.1M ($0.00 diluted EPS) vs $0.1M ($0.01) prior year.
- Adjusted EBITDA $22.4M (+8%); operating income $4.1M (+147%); net income $0.9M vs $0.0M prior year.
- FY2024 guidance: high-single-digit revenue growth; Adjusted EBITDA margin in high-teens (above 17.8%).
- Joint venture SI Wound Care (with Sanara MedTech) expected to generate meaningful revenue in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024011061/0001628280-24-011061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024011061/infu-20240314.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-011061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer